Robert A. Lenz sold $208k of NMRA
Head of R&D at Neumora Therapeutics, Inc.. 13,823 shares at an average of $15.06, traded Oct 9, 2024, filed Oct 11, 2024.
Score components
- +15RoleOfficer
- +12Trade size$208k at market
- 0Share of holdings soldSold 4.2% of holdings
- +8Cluster2 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001610717-24-000505, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 9, 2024 | SOpen-market sale Common Stock10b5-1 | -5,563 | $15.01 | $84k | 322,966 | Oct 11, 2024 |
| Oct 10, 2024 | SOpen-market sale Common Stock10b5-1 | -8,260 | $15.09 | $125k | 314,706 | Oct 11, 2024 |
Related signals
Other insiders at Neumora Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 3Weak | Neumora Therapeutics, Inc. | Daljit Singh Aurora Chief Strategy Officer | $14k 8,565 shares | -9% | |
| 3Weak | Neumora Therapeutics, Inc. | Paul L Berns See Remarks | $23k 13,871 shares | -0% | |
| 23Weak | Neumora Therapeutics, Inc. | Matthew K Fust director | $371k 21,788 shares | -78% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.